Figure 3.

PD inhibits HCC cell growth both in vitro and in vivo

(A) Cell viability measurement of HepG2, Hep3B, and LO2 cells treated with PD at increasing concentrations (up to 6 μM) for 12, 24, and 48 h by WST-1 assays. (B) The cell death of HepG2 and Hep3B cells stimulated with PD (0–6 μM, 24 h) was detected by PI staining, and the PI-positive cells were quantified. (C) Representative images of excised Hep3B tumors from mice with intragastric administration (i.g.) at 4 mg/kg or intraperitoneal injection (i.p.) at 2 mg/kg (n = 6). (D) Tumor growth curves; data are represented as mean ± SEM. (E) IHC staining for Ki-67. (F) An overview of the establishment of HCC MiniPDX model. (G) Scatterplot showing the relative proliferation rate of the HCC MiniPDX model upon treatment with PD (i.g. 4 mg/kg). n = 6; data are represented as mean ± SD; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.